Tricaprilin Phase 3 AD Study
Tricaprilin Phase 3 AD Study
ClinicalTrials.gov ID: NCT05809908
Sponsor: Cerecin
Information provided by: Cerecin (Responsible Party)
Last Update Posted: 2023-04-12
Brief Summary:
The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on cognition, activities of daily living, resource utilisation, safety and tolerability, in subjects with mild to moderately severe probable AD.
This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design in up to 535 participants.
Official Title:
A Phase III, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease
Intervention / Treatment:
- Drug: Tricaprilin
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Estimated) | 2024-01 |
| Primary Completion (Estimated) | 2026-01 |
| Study Completion (Estimated) | 2027-01 |
| Enrollment (Estimated) | 535 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
AC-22-027
|